Oddo BHF Asset Management Sas Takes $8.48 Million Position in Catalent, Inc. (NYSE:CTLT)

Oddo BHF Asset Management Sas purchased a new position in shares of Catalent, Inc. (NYSE:CTLT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 140,000 shares of the company’s stock, valued at approximately $8,480,000.

Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in shares of Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after buying an additional 185 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after buying an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after buying an additional 229 shares during the period. Vanguard Personalized Indexing Management LLC increased its position in Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after acquiring an additional 278 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Catalent by 26.9% during the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after acquiring an additional 278 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $63.40.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 in the last three months. 0.31% of the stock is currently owned by company insiders.

Catalent Stock Down 0.3 %

Shares of NYSE CTLT opened at $63.07 on Friday. The firm has a fifty day simple moving average of $60.25 and a two-hundred day simple moving average of $58.91. Catalent, Inc. has a 12 month low of $37.03 and a 12 month high of $63.25. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. Equities research analysts expect that Catalent, Inc. will post 0.78 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.